Product Profiles Autism Spectrum Disorders Underserved market eagerly anticipates pipeline trial data

We are sorry but this premium report expired!

This market research, not available anymore on the publisher's website, was withdrawn from our database.

To get an alternative report, you can either :

  • Have a look at the list of documents hereafter
  • Launch a new search below

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

DOWNLOAD THESE REPORTS NOW!

Physician Views: New data for Novartis% LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

Physician Views: New data for Novartis% LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

  • $ 645
  • Industry report
  • by Firstword Pharma
  • Oct 2014

The potential blockbuster status of Novartis' LCZ696 has seemingly been cemented in the eyes of the Street thanks to solid results from the Phase III PARADIGM-HF study that were presented over the weekend. Indeed, the chronic heart failure agent is believed to represent both a significant growth drive ...

Industries: Pathology | Countries: United States

MicroTransponder Inc. - Product Pipeline Analysis, 2014 Update

MicroTransponder Inc. - Product Pipeline Analysis, 2014 Update

  • $ 750
  • Company report
  • by Global Data
  • October 2014
  • 27 pages

Summary MicroTransponder Inc. (MicroTransponder) is a medical device company. The company develops neurostimulation solutions to treat neurological diseases. Its lead product serenity system is used to treat tinnitus. MicroTransponder's product serenity system combines with an existing therapy called ...

Industries: Pathology | Countries: United States

Malignant Melanoma: KOL Insight

Malignant Melanoma: KOL Insight

  • $ 6 495
  • Industry report
  • by Firstword Pharma
  • October 2014
  • 125 pages

Malignant Melanoma: PD-1 inhibitors revolutionise treatment is a comprehensive report with insights from 12 leading US and European KOLs offering their latest views on current and late-stage pipeline products, why and when they would prescribe them, and the factors likely to affect their future positioning ...

Industries: Pathology | Countries: United States

GeneNews Limited (GEN) - Product Pipeline Analysis, 2014 Update

GeneNews Limited (GEN) - Product Pipeline Analysis, 2014 Update

  • $ 750
  • Company report
  • by Global Data
  • October 2014
  • 30 pages

Summary GeneNews Limited (GeneNews) is a cancer diagnostics company. The company develops, licenses and commercializes genomic-based clinical laboratory tests. It develops diagnostic tests such as, ColonSentry and SentinelGx. GeneNews ColonSentry is a blood test for colorectal cancer and SentinelGx is ...

Industries: Pathology | Countries: United States, Canada

US Biomarkers, Inc. - Product Pipeline Analysis, 2014 Update

US Biomarkers, Inc. - Product Pipeline Analysis, 2014 Update

  • $ 750
  • Company report
  • by Global Data
  • October 2014
  • 28 pages

Summary US Biomarkers, Inc. (US Biomarkers) is a molecular diagnostics company. The company provides disease specific biomarkers for cancer and neurodegenerative diseases using DNA methylation. It offer services such as identification, monitoring, characterization, and treatment. US Biomarkers also provides ...

Industries: Pathology | Countries: United States

Affymax, Inc. (Symbol:AFFY) SWOT Analysis, Strategy, Revenues and Profits

Affymax, Inc. (Symbol:AFFY) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • by Global Data
  • October 2014
  • 25 pages

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days. Affymax, Inc. SWOT Analysis report provides you a strategic analysis ...

Industries: Pathology | Countries: United States

AGA Medical Holdings, Inc. (Symbol:AGAM) SWOT Analysis, Strategy, Revenues and Profits

AGA Medical Holdings, Inc. (Symbol:AGAM) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • by Global Data
  • October 2014
  • 15 pages

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days. AGA Medical Holdings, Inc. SWOT Analysis report provides you a strategic ...

Industries: Pathology | Countries: United States

ALung Technologies, Inc. SWOT Analysis, Strategy, Revenues and Profits

ALung Technologies, Inc. SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • by Global Data
  • October 2014
  • 15 pages

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days. SWOT Analysis report provides you a strategic analysis and detailed ...

Industries: Pathology | Countries: United States

Ampio Pharmaceuticals, Inc. (Symbol:AMPE) SWOT Analysis, Strategy, Revenues and Profits

Ampio Pharmaceuticals, Inc. (Symbol:AMPE) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • by Global Data
  • October 2014
  • 25 pages

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days. Ampio Pharmaceuticals, Inc. SWOT Analysis report provides you a strategic ...

Industries: Pathology | Countries: United States

Anthera Pharmaceuticals‚ Inc. (Symbol:ANTH) SWOT Analysis, Strategy, Revenues and Profits

Anthera Pharmaceuticals‚ Inc. (Symbol:ANTH) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • by Global Data
  • October 2014
  • 25 pages

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days. Anthera Pharmaceuticals‚ Inc. SWOT Analysis report provides you ...

Industries: Pathology | Countries: United States

24/7 Customer Service

You can call our customer service 24 hours a day / 7 days a week

  • +1 718 618 4302

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.